Table 1.

Three novel cross-cancer pleiotropic variants were identified to associated with colorectal cancer risk

SNP	Chr	Region	Located gene	Effect/ref allele	Discovery stage			Validation stage			Reported cancer	P -pleiotropy a
					OR (95% CI)	P-value b	FDR b	OR (95% CI)	P-value c	FDR c
rs9277378	6	6p21.32	HLA-DPB1	G/A	0.92 (0.88 to 0.95)	7.86 × 10−6	0.010	0.95 (0.92–0.98)	0.002	0.011	Lymphoma	8.31 × 10−12
rs2230469	10	10p12.2	PIP4K2A	C/T	1.07 (1.04 to 1.10)	9.70 × 10−6	0.010	1.04 (1.01–1.08)	0.009	0.022	Leukemia	1.01 × 10−4
rs143190905	20	20q13.33	RTEL1	T/G	0.89 (0.83 to 0.94)	5.37 × 10−5	0.020	0.94 (0.89–0.99)	0.023	0.038	Cutaneous melanoma	2.95 × 10−6

^aThe P_pleiotropy was derived from the pleiotropy analysis via PLACO utilizing GWAS summary data of CRC and each of the reported cancers.

^bThe P-value and FDR were derived from the CRC GWAS meta-analysis.

^cThe P-value and FDR were derived from the validation analysis in UK Biobank population.